Evidence map›Paper›PMID 32995770›Full record

ArticlebioRxiv : the preprint server for biology2020

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.

Ge Song, Wan-Ting He, Sean Callaghan, Fabio Anzanello, Deli Huang, James Ricketts, Jonathan L Torres, Nathan Beutler, Linghang Peng, Sirena Vargas and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 97 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Ge SongDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Wan-Ting HeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Sean CallaghanDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Fabio AnzanelloDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Deli HuangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
James RickettsDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Jonathan L TorresDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Nathan BeutlerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Linghang PengDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Sirena VargasDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Jon CassellDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Mara ParrenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Linlin YangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Caroline IgnacioDivision of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Davey M SmithDivision of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
James E VossDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
David NemazeeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Andrew B WardIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Thomas RogersDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Raiees AndrabiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Scripps Research Institute · USUniversity of California San Diego · US

Funding

Knock-in mice expressing germline-reverted broadly neutralizing HIV antibodiesR01AI073148 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2007 to 2023
$8.2M
Germline targeting influenza immunogensR01AI132317 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2017 to 2021
$7.0M
Knock-in mice expressing germline-reverted broadly neutralizing HIV antibodiesR56AI073148 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2013 to 2013
$514k
NIAID NIH HHS R01 AI073148NIAID NIH HHS R01 AI132317NIAID NIH HHS R56 AI073148
6 · The paper itself

Abstract

Pre-existing immune responses to seasonal endemic coronaviruses could have profound consequences for antibody responses to SARS-CoV-2, either induced in natural infection or through vaccination. Such consequences are well established in the influenza and flavivirus fields. A first step to establish whether pre-existing responses can impact SARS-CoV-2 infection is to understand the nature and extent of cross-reactivity in humans to coronaviruses. We compared serum antibody and memory B cell responses to coronavirus spike (S) proteins from pre-pandemic and SARS-CoV-2 convalescent donors using a series of binding and functional assays. We found weak evidence of pre-existing SARS-CoV-2 cross-reactive serum antibodies in pre-pandemic donors. However, we found stronger evidence of pre-existing cross-reactive memory B cells that were activated on SARS-CoV-2 infection. Monoclonal antibodies (mAbs) isolated from the donors showed varying degrees of cross-reactivity with betacoronaviruses, including SARS and endemic coronaviruses. None of the cross-reactive mAbs were neutralizing except for one that targeted the S2 subunit of the S protein. The results suggest that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.

Identifiers

PMID32995770
PMCPMC7523096
OpenAlexW3088826295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.